SUMMARY The hypotensive efficacy of a potent new renin inhibitor (iVa-isovaleryl-L-histidyl-Lprolyl-L-phenylalanyl-L-hlstidyl-ACHPA-L-leucyl-L-phenylalanyl amide) containing (3S,4S)-4-amino-5-cyclohexyl-3-hydroxy pentanoic acid (ACHPA) was compared with the converting enzyme inhibitor (enalaprilat) (MK-422) in conscious one-kidney dogs before and after tightening a renal artery clamp. Dose-response curves to 0.003 to 0.1 mg/kg/min i.v. infusions of the ACHPA-containing renin inhibitory peptide or enalaprilat (0.003-0.1 mg/kg i.v. bolus) were obtained in one-kidney dogs before and 3 days and 14 days after renal artery constriction. The ACHPA-containing renin inhibitory peptide and enalaprilat maximally decreased blood pressure by 10 ± 2 and 9 ± 2 mm Hg before constriction and by 12 ± 2 and 12 ± 4 mm Hg in dogs treated 14 days after renal artery constriction, respectively. Glomerular filtration rate and effective renal plasma flow were unaltered or slightly improved. In sharp contrast, both compounds elicited significant, dose-related decreases in blood pressure ( -26 ± 4 and -20 ± 4 mm Hg, respectively), glomerular filtration rate ( -21 ± 3 and -23 ± 3 ml/min), and renal plasma flow ( -45 ± 14 and -48 ± 13 ml/min) in dogs examined 3 days after renal artery constriction. These data demonstrate that ACHPA-containing renin inhibitory peptide and enalaprilat are equally effective antihypertensive agents in dogs with renin-dependent renovascular hypertension and lend credence to the contention that the renin-angiotensin system supports renal function in hypertensive states in which renin levels are elevated. (Hypertension 9: 150-156, 1987) KEY WORDS • blood pressure • renal function • renin-angiotensin system
COMPARISON OF A RENIN INHIBITOR AND ENALAPRILAT/Sm/r/i et al.
Recently, several groups have reported that some renin substrate analogues show a high degree of specificity as competitive renin inhibitors in vitro and are effective hypotensive agents in rats in which blood pressure is supported by an infusion of exogenous renin, 13 
'
H in sodium-deficient dogs, 14 " 16 in normotensive and hypertensive sodium-deficient monkeys, 17 and in sodium-deficient humans. 18 One such peptide contains the unusual amino acid statine, a feature that contributes to its efficacy as a renin inhibitor. 13 Replacement of statine with (3S,4S)-4-amino-5-cyclohexyl-3-hydroxy pentanoic acid (ACHPA) has led to a new series of peptides possessing a more potent activity profile.
Afa-Isovaleryl-L-histidyl-L-prolyl-L-phenylalanyl-Lhistidyl-(3S,4S)-[4-amino-5-cyclohexyl-3-hydroxy]-pentanoyl-L-leucyl-L-phenylalanyl amide is a potent new ACHPA-containing renin inhibitory peptide (ACRIP) that has been shown to specifically inhibit rat, rabbit, dog, and human plasma renins in vitro (IC 50 = 21 nM, 0.54 nM, 1.9 nM, and 0.17 nM, respectively). 19 The present study compared the cardiovascular and renal effects of ACRIP with those of enalaprilat (MK-422), an ACE inhibitor, in conscious dogs. To evaluate ACRIP in renin-dependent and renin-independent hypertensive states, the compound was infused into conscious one-kidney dogs on three occasions: 1) before renal artery constriction (RAC), 2) during the initial phase of experimental renovascular hypertension when PRA was elevated, and 3) during chronic experimental hypertension after PRA had returned to normal levels. The hypotensive activity of ACRIP was comparable to that of the ACE inhibitor, enalaprilat {N[(S)-1 -carboxy-3-phenylpropyl]-L-Ala-L-Pro) at all stages of the experiment and was most evident during the early phase of experimental renovascular hypertension.
Materials and Methods
Conditioned female mongrel dogs (Haycock Farms, Quakertown, PA, USA) weighing 10 to 25 kg and maintained on a normal sodium diet (60-65 mEq/day) were unilaterially nephrectomized under sterile conditions using halothane/NO/O 2 anesthesia. Chronic indwelling iliac arterial and venous Tygon catheters were implanted, and the free ends were exteriorized between the shoulder blades. The dogs were allowed to recover for several days, during which time they were trained to stand calmly in nylon mesh support slings (Alice King Chatham, Los Angeles, CA, USA).
Two to 3 weeks later, the renal artery of the remaining kidney was exposed through a flank incision made under sterile operating conditions. An adjustable clamp was placed around the artery, and an electromagnetic flow probe (Carolina Medical Instruments, King, NC, USA) temporarily was positioned distal to the clamp to measure renal blood flow. Once flow had stabilized, the clamp was tightened until the flow was reduced by 55 to 60%, a procedure previously reported to produce benign renal hypertension in one-kidney dogs within 24 hours. 5 The flow probe was removed, and the animal was allowed to recover.
Each animal was treated with several predetermined doses of either ACRIP or enalaprilat on three occasions: 1) when the dog had recovered from the unilateral nephrectomy, 2) 3 days after RAC, and 3) 14 days after RAC. For each dose-response determination, the dog was placed in a support sling and a sterile Foley catheter was inserted into the bladder for the collection of timed urine samples. At least 1 hour before beginning each experiment, a priming injection containing creatinine (50 mg/kg) andp-aminohippurate (PAH), 8 mg/kg, in 0.9% sterile saline was administered as a bolus into the indwelling venous catheter and followed by a continuous 1 ml/min sustaining infusion of creatinine and PAH (1.0 and 0.3 mg/kg/min, respectively). After the 1 hour equilibration period, the bladder was emptied and rinsed with 25 ml of sterile distilled water, and the experiment was begun.
Once two 30-minute control urine collections were obtained, four doses of the test compound were administered at 1 hour intervals, during which two 30-minute clearance periods were observed at each dose. ACRIP was added to the creatinine-PAH solution and, because of its relatively short half-life, was infused continuously for an hour at rates of 0.003, 0.01, 0.03, and 0.1 mg/kg/min. Enalaprilat was dissolved in 0.9% saline and injected intravenously as a bolus for cumulative doses of 0.003, 0.01, 0.03, and 0.1 mg/kg. Each dog was randomly assigned one of the test agents and received only that compound during the 3-week period. In each experiment, blood pressure was monitored continuously by a pressure transducer (Micron Instruments, Los Angeles, CA, USA) connected to the indwelling iliac arterial catheter and placed at heart level. Heart rate (HR) was derived electronically from the pressure pulses. These parameters were recorded simultaneously on punched paper tape (data obtained at 1-minute intervals) by a data logger (Digitec; United Systems, Dayton, OH, USA) and displayed on a Gould 2600 strip chart recorder (Cleveland, OH, USA). The minute-to-minute HR and MAP data were averaged later for each 30-minute period, and these mean values were used in all subsequent analyses.
Arterial blood samples for measurements of hematocrit and plasma electrolyte, creatinine, and PAH concentrations were drawn at the midpoint of each clearance period and placed in heparinized tubes. The volume of urine collected throughout each 30-minute interval was determined gravimetrically. Finally, an arterial blood sample for PRA analysis was collected in a chilled test tube containing disodium EDTA at the end of each period. Urine and plasma samples were analyzed for sodium, potassium, and chloride content using ion-selective electrodes (C800 System, Technicon Instruments, Tarrytown, NY, USA), and urinary electrolyte excretions were calculated by standard formulas. Creatinine and PAH concentrations were determined using a colorimetric assay adapted to an autoanalyzer (Technicon Instruments). Effective renal plasma flow (ERPF) and glomerular filtration rate VOL 9, No 2, FEBRUARY 1987 (GFR) were estimated by the renal clearances of PAH and creatinine, respectively. PRA was measured by radioimmunoassay (Clinical Assays, Cambridge, MA, USA) of samples generated at pH 6.0 for 1 hour. Upper and lower limits of detection were 56 and 0.22 ng angiotensin I/ml/hr, respectively. All procedures were performed in accordance with our institutional guidelines for animal care and use.
The smaller group size in the post-RAC groups, compared with the large pre-RAC numbers, reflects the fact that several dogs failed to become hypertensive following RAC, and others died shortly after the procedure. Furthermore, malignant hypertension developed in two of the five dogs in the ACRJP-treated group during the second week of the study. The individual response profiles observed in the remaining three ACRTP-treated dogs were, however, representative of the overall group responses at the previous time points (normotensive and 3 days post-RAC).
Statistical differences between treatment means were ascertained by analysis of variance for repeated measures. Significant deviations from controls were detected by Dunnett's t test (p < 0.05). Student's / test (p < 0.005) was used to compare differences between ACRIP and enalaprilat treatments at specific time points. Figure 1 ) at several doses in normotensive dogs without affecting HR (Table 1) . ACRIP treatment did not alter either ERPF (see Table 1 ) or GFR ( Figure 2 ) in normotensive dogs. Administration of ACRIP resulted in a significant, dose-related natriuresis and a less consistent diuresis in normotensive dogs (see Table 1 ). The initial dose of ACRIP reduced arterial PRA (Table 1) to levels approaching the lower limits of our assay sensitivity. Therefore, any additional decreases would not have been detected. Three days after RAC, when arterial pressure was increased by an average of 25 ± 2 mm Hg, increasing doses of ACRIP progressively lowered MAP until a maximum decrease of 26 ± 4 mm Hg was reached during the infusion of 0.1 mg/kg/min. HR rose several times during ACRIP infusion (see Table 1 ), but the response was not consistent nor dose-related. In this early phase of experimental hypertension, ACRIP produced significant reductions in GFR (see Figure 2) and small, nonsignificant decreases in ERPF (see Table 1 ). Urine flow and natriuresis (see Table 1 ) were significantly depressed by ACRIP, as were excretion rates of potassium (from 4 0 ± 7 t o l O ± 2 /iEq/min) and of chloride (from 55 ± 14 to 10 ± 3 /iEq/min). Again, all doses of ACRIP significantly reduced PRA from 2.55 ± 0.67 ng angiotensin I/ml/hr to undetectable levels (see Table 1 ).
Results

ACRIP produced small but statistically significant falls in MAP (
In dogs with chronic renovascular hypertension (14 days post-RAC), ACRIP administration diminished PRA to nearly undetectable levels (see Table 1 ) and decreased potassium excretion from 21 ± 4 to 10 ± 2 AiEq/min at the highest dose. There were no statistical- 
FIGURE 1. MAP in dogs treated with ACHPA-containing renin inhibitory peptide (ACRIP; A) or enalaprilat (MK-422; B) at various stages in the development of one-kidney, one clip hypertension. The values represent the mean ± SEM for normotensive dogs (*), dogs 3 days after renal artery constriction (RAC; • ) , dogs 14 days after RAC (A), and dogs with malignant hypertension (o). Single (p<0.05) and double (p<0.01) asterisks indicate that the value is significantly different from the corresponding predrug value. The number of animals in each treatment group is shown in parentheses.
ly significant changes in the other measured variables.
During the second week of the study, two dogs exhibited signs of malignant hypertension, such as severely elevated blood pressure (182 ± 1 mm Hg) and poor renal function (GFR = 18 ± 5; ERPF = 77 ± 46), and one of the dogs exhibited hyperreninemia (12.56 ng angiotensin I/ml/hr). When challenged with ACRIP, MAP fell dramatically in these dogs (see Figure 1A) .
The hypotensive and HR responses to enalaprilat in normotensive dogs (Table 2 ; see Figure IB ) were nearly identical to those produced by ACRIP. The ERPF (see Table 2 ) and GFR (see Figure 2 ) tended to improve following treatment with enalaprilat but, as with ACRIP, a clear dose-response relationship could not be defined. However, enalaprilat did elicit a doserelated saluresis and diuresis (see Table 2 ). PRA was significantly elevated by all doses of enalaprilat.
During the early phase of experimental renovascular hypertension, enalaprilat significantly decreased MAP at all but the lowest dose (see Figure IB) . At no time was MAP lower than that measured in the ACRTPtreated dogs. The changes in HR (see Table 2 ) were not significant as a group, even though tachycardia was observed in several dogs at the higher dose of enalaprilat. The significant reductions in ERPF (see Table  2 ) and GFR (see Figure 2 ) produced by administration of the ACE inhibitor were similar to those induced by ACRIP infusion. Although enalaprilat tended to attenuate urine flow and electrolyte excretion in these animals, only the fall in potassium excretion (from 28 ± 7 to 8 ± 2 /i.Eq/min) was significant. As expected, ACE inhibition produced dose-related increases in PRA (see Table 2 ).
The highest dose of enalaprilat elicited a small but significant drop in MAP in dogs with established experimental renovascular hypertension (see Figure IB) . PRA was elevated by all doses of the compound in these animals, but no other significant changes were observed (see Table 2 and Figure 2) .
The depressor responses to ACRIP and to enalaprilat in normotensive dogs and in each phase of experimental hypertension are summarized in Figure 3 . At no time during the course of the study were the maximal hypotensive responses produced by ACRIP significantly different .from those obtained with enalaprilat.
Discussion
Most of the investigations seeking to establish the role of the renin-angiotensin system in the genesis of hypertension in various experimental models have been fraught with technical difficulties. The intrinsic agonistic activity associated with the angiotensin II analogues rendered these compounds less than ideal tools for examining the renin-angiotensin system. Likewise, the involvement of converting enzyme in at least two different biochemical pathways has led to the generation of contradictory results when ACE inhibitors have been used to establish cause and effect relationships. The recent advent of peptides that interfere directly with the enzyme renin has provided investigators with a precise antagonist with which to experimentally inhibit the renin-angiotensin system. These potent and highly specific peptides, which should be devoid of any actions outside of the renin-angiotensin system, have been shown to be effective hypotensive agents in animal models in which PRA was elevated. 13 " 17 The present study compared the effects of the most potent of these new specific renin inhibitors, ACRIP, with those of the ACE inhibitor enalaprilat in an effort to define precisely the role of the reninangiotensin system in canine experimental renovascular hypertension.
In the current study, moderate RAC in unilaterally nephrectomized dogs produced a sustained hypertension accompanied by an elevated PRA during the first week (see Figure 1 and Tables 1 and 2 ). During the second week, PRA values declined while MAP remained elevated. Administration of the ACE inhibitor enalaprilat significantly reduced MAP during the early phase of experimental hypertension but yielded only modest falls in chronic hypertensive and normotensive dogs (see Figure 1) . Similar results have been obtained by others, 2 ' *"* who have suggested that the hypotensive efficacy of the ACE inhibitors is related to the preexisting level of PRA in the subject; an explanation that assumes that the hemodynamic changes associated with ACE inhibition resulted solely from reduced formation of the pressor hormone angiotensin II. Addi- hibitor aprotinin. 12 These data supported the contention that potentiation of the kallikrein-kinin system may contribute to the hemodynamic actions of captopril. In an effort to resolve this issue, several investigators have directly compared the antihypertensive activity of the ACE inhibitors with that of the renin inhibitors in vivo. Leckie et al. 20 and Wood et al. 21 were unable to demonstrate additional hypotensive effects when converting enzyme inhibitors were administered to animals receiving infusions of a renin inhibitor. These data contrast with those of Oldham et al. 16 and Blaine et al. 22 who have reported additional, albeit small, reductions in arterial pressure attributable to ACE inhibition under similar circumstances. The reasons for the discrepancy remain unclear. In the present study, short-term administrations of the ACE inhibitor enalaprilat and ACRIP, a novel and potent renin inhibitor, had equally hypotensive effects in normotensive and hypertensive one-kidney dogs (see Figure 3) . Additionally, both of these compounds were most active in dogs 3 days post-RAC, a time when MAP is thought to be supported largely by the renin-angiotensin system.
FIGURE 2. Glomerular filtration rate (GFR) in dogs treated with ACHPA-containing renin inhibitory peptide (ACRIP; A) or enalaprilat (MK-422; B) at various stages in the development of one-kidney, one clip hypertension. The values represent the mean ± SEM for normotensive dogs (•) and dogs 3 days (•) and 14 days (A) after renal artery constriction. Single (p<0.05) and double (p<O.OI) indicate that the value is sig-
TABLE 2. Effects of Administration of Enalaprilat on Selected Parameters at Various Stages in the Development of One-Kidney, One Clip Hypertension
-
7 Some concern has been raised regarding the effects of surgery on renin release in the one-kidney hypertensive dog model and how this might affect the observed parameters after operation. Although our study did not include a sham-operated control group, others 23 - 24 have shown that surgically induced renin release returns to presurgical levels within 24 hours. In addition, Gutmann et al. 25 showed that reducing the renal blood flow to the remaining kidney in a onekidney, one clip conscious dog 9 days postoperatively elicited renin release within minutes. Since the PRA patterns observed in the present study follow the patterns routinely seen in one-kidney, one clip renal hypertensive dogs, it seems unlikely that our findings 3 days post-RAC result from surgical trauma.
Interestingly, renal function also appeared dependent upon the renin-angiotensin system 3 days post-RAC, since treatment with either enalaprilat or ACRIP diminished each measure of renal hemodynamics and excretory function (see Figure 2 on p. 153 and Tables 1  and 2 , opposite). These findings were consistent with the suggestion of Hall and co-workers 26 
27 that angiotensin II-induced vasoconstriction of the renal efferent arterioles was necessary for autoregulation of GFR in ischemic kidneys. These authors showed that angiotensin II levels increased during reduction in renal blood flow in untreated dogs, leading to enhanced efferent arteriolar tone and maintenance of glomerular perfusion pressure. However, when the vasoconstricting actions of the renin-angiotensin system were inhibited by [Sar ]angiotensin II, a competitive antagonist, the renal efferent arterioles dilated, and filtration pressure was reduced. Additionally, ACE inhibitors diminished renal function in patients with a single stenotic kidney and in patients with bilateral renal artery stenoses. 28 " 32 Withdrawal of the inhibitor restored renal function in those patients. In the present study, administration of enalaprilat or ACRIP compromised renal function in the one-kidney renovascular hypertensive dogs only when PRA was elevated 3 days after RAC. Renal function had returned to normal by the time these animals were reexamined 14 days after RAC. These data are consistent with the hypothesis that angiotensin II is essential for autoregulation in ischemic kidneys. VOL 9, No 2, FEBRUARY 1987 In conclusion, a potent new renin inhibitor, ACRIP, and the ACE inhibitor enalaprilat produced quantitatively similar effects on MAP and renal function in conscious normotensive dogs and in dogs in two stages of experimental renovascular hypertension. Both compounds were most efficacious in dogs with acute renovascular hypertension associated with an elevated PRA and were modestly depressor in normotensive dogs and dogs with chronic renovascular hypertension. Each agent compromised renal function in animals in which renin levels were elevated, demonstrating that the renin-angiotensin system is a major component of renal autoregulation in hypertensive, as well as normotensive, animals. 26 ' 27 By no measure was enalaprilat more effective than ACRIP, indicating that suppression of the renin-angiotensin system was the primary, if not the sole, antihypertensive effect during short-term treatment with an ACE inhibitor in this model.
